The first-in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial hypercholesterolemia.
The largest genetic analysis of abdominal aortic aneurysm (AAA) carried out to date has identified almost 100 new risk variants linked to the disorder. The study also highlighted a possible therapeutic target for this pathology that, at the moment, has no treatment.
Every 33 seconds, a life is lost to cardiovascular disease, making it the primary cause of death for both men and women.Understanding your cholesterol level pl